{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:41:57Z","timestamp":1772160117509,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007885","name":"European Association for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of initiating insulin degludec\/liraglutide (IDegLira) in patients with type 2 diabetes (T2D) who had discontinued pretrial sulphonylureas (SUs) or dipeptidyl peptidase\u20104 inhibitors (DPP4is) versus patients not previously treated with these regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In DUAL II, patients with T2D uncontrolled on basal insulin and metformin \u00b1 SU\/glinides were randomized to insulin degludec or IDegLira (both capped at 50\u2009U). In DUAL IX, patients were randomized to insulin glargine U100 (no maximum dose) or IDegLira, as add\u2010on to sodium\u2010glucose co\u2010transporter\u20102 inhibitors \u00b1 oral antidiabetic drugs. In this post hoc analysis, patients were grouped according to pretrial use of SU (DUAL II) or DPP4i (DUAL IX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regardless of pretrial SU\/DPP4i use, IDegLira was favourable versus insulin comparators with respect to change in HbA1c and body weight. Lower hypoglycaemia rates and comparable end\u2010of\u2010trial daily insulin dose were achieved with IDegLira, regardless of pretrial regimen. There was no clinically relevant increase in mean self\u2010measured blood glucose in the early weeks after IDegLira initiation. There was no statistically significant interaction between the randomized treatments and previous SU\/DPP4i use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      IDegLira was more favourable compared with degludec or glargine U100 in terms of change in HbA1c and body weight, regardless of antecedent treatment. Clinicians should be aware of a potential transient rise in self\u2010measured blood glucose when transitioning therapy in patients\n                      <jats:italic>.<\/jats:italic>\n                      This shows that SUs\/DPP4is can be safely discontinued, without deterioration in glycaemic control when initiating IDegLira, allowing a simplified treatment regimen.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13944","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T01:00:18Z","timestamp":1576803618000},"page":"658-668","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Benefits of insulin degludec\/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase\u20104 inhibitors upon initiation of degludec\/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials"],"prefix":"10.1111","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-5254","authenticated-orcid":false,"given":"Andrej","family":"Janez","sequence":"first","affiliation":[{"name":"University Medical Centre Ljubljana  Ljubljana Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"\u0150rsy","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Stachlewska","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Salvesen\u2010Sykes","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc., Plainsboro, New  Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana K.","family":"Billings","sequence":"additional","affiliation":[{"name":"NorthShore University Health System\/University of Chicago Pritzker School of Medicine  Skokie, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-9630","authenticated-orcid":false,"given":"Athena","family":"Philis\u2010Tsimikas","sequence":"additional","affiliation":[{"name":"Scripps Whittier Diabetes Institute, San Diego  California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2016.09.003"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.2275"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe0804182"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3372-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7345"},{"key":"e_1_2_8_9_1","first-page":"303","article-title":"Potential glycemic overtreatment in patients >\/=75\u2009years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study","volume":"8","author":"Penfornis A","year":"2015","journal-title":"Diabetes Metab Syndr Obes."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0599"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00198"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2017-0153"},{"key":"e_1_2_8_13_1","unstructured":"Novo Nordisk. XULTOPHY\u00ae 100\/3.6 (insulin degludec and liraglutide injection) for subcutaneous use.2019. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208583s012lbl.pdf. Accessed September 2 2019."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12303"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1252"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12892"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13666"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_8_23_1","unstructured":"Good Clinical Practice 1996 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01258.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S78008"},{"key":"e_1_2_8_26_1","first-page":"69","article-title":"American Association of Clinical Endocrinologists AACE\/ACE comprehensive type 2 diabetes management algorithm","volume":"25","year":"2017","journal-title":"Endocr Pract"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.102"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0699"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13182"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13944","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:39:26Z","timestamp":1761892766000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/dom.13944"],"URL":"https:\/\/doi.org\/10.1111\/dom.13944","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13944\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13944\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]},"assertion":[{"value":"2019-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}